Thanks for your input. Very in. Are you saying that the cryogenic LNAs they advertised but couldn't make are different from what's being shown as an available SKU on their website (https://www.amplitechinc.com/product-details/aptc3-04001000-1k00-d4-v), or is this SKU not real? I'm guessing you mean that they do have cryogenic LNAs but not up to spec with what they claimed to be capable of delivering at the APS show four years ago.

Also for what it's worth, the CEO salary does not seem to be that inflated and was decreased from 2019 to 2020 per an article about it that they reposted on their own site (https://www.amplitechinc.com/news/what-did-amplitech-group-s-nasdaq-ampg-ceo-take-home-last-year-). The "quantum computing" stuff in the PRs sounds scammy but it looks like a real product category signifying a standard of low signal noise. I guess for me, I can imagine that the niches are small enough that they could be competitive through an engineering advantage, because they cater to a customized components market rather than a consumer mass market. There may be a couple of tiny niches where they are competitive at producing the desired specs. What I don't like is the last acquisition. Seems like maybe it was equivalent to paying $8m+ just to get a customer list from the acquired company. Which would cast doubt on their ability to market their own products effectively. I think that it's a real company but with significant risk that their addressable market will remain very niche and the current market cap is inflated by unrealistic growth expectations, but on the other hand maybe the growth of their target industries is going to give them significant growth as well. There's also the fact that such a low free float can run quite hard with just one solid patent PR or one exceptionally large order. Altogether it seems like a reasonable play given the current cash position but I guess if the next earnings is bad then it could be brutal for the share price.

If that's true then the PRs I quoted basically mean AMPG's management are tantamount to con artists. Which could be true, but it raises the question why Intracoastal and Sabby invested. I guess it comes down to them either having patentable innovations giving them a larger addressable market, or not. Either they're telling the truth, or just producing smoke and mirrors to sucker investors. Usually when smoke and mirrors is the answer it's clear based on past behavior such as past PRs containing lies or broken promises. Have they already issued previous PRs about having new patents forthcoming in past years such as prior to 2020, and nothing ever came of them?

I realize it was a lot to read. I'll simplify for you: they're calling the LNA chips from early November "proprietary" "initial chip designs" which suggests that these are new products for a new market niche related to full 5G throughput capability for 5g devices. Do you think that they're lying about having a novel proprietary design that has a competitive advantage worth patenting, e.g. if it can achieve this 1 gbps throughput with better costs than competitors? I'm trying to communicate with you in plain English because you seem knowledgeable about the company and the type of technology, but is it too much to hope for a reply from you in plain English that contains something intelligible other than insults? Lmao. I know we're here in good fun. Would appreciate your insight if you have any. If not all good. Enjoy your day.

Thanks for sharing your informed opinions. Questions: it seems that the LNA market is a new product line niche for AMPG, at least that is how the most recent earnings PR makes it sound:

"In early November, AmpliTech completed and released initial chip designs incorporating its LNA and other technologies for semiconductor fabrication and expects initial production units to be available by the end of Q1’22."

It sounds like they're claiming that they have developed a new line of products that have never been sold before, which increase the targetable market for their products to include new applications in new product categories.

This raises the questions:

(1) Are the new LNA chip designs actually proprietary and innovative? Or are they just generic technology within what is a new product category for AMPG to be selling in?

(2) If the new LNA chip designs are not proprietary, what is AMPG's competitive advantage? (Answer would probably be "none.") But the PR from October claims that the designs are proprietary (https://fintel.io/doc/sec-amplitech-group-inc-1518461-ex991-2021-october-04-18905-1231).

(3) The CEO had mentioned in a previous PR that current chips don't provide enough throughput to fully take advantage of 1 Gbps 5G speeds, and suggested or implied that AMPG's new chips will solve this problem. One must infer that either (A) the current chips he's talking about are chips in the same cost range as AMPG's, meaning that AMPG has a cost or margin advantage for delivering higher throughput chips than competitors, or (B) current chips from competitors cannot achieve these speeds.

(B) is obviously ridiculous -- it can't be true that AMPG is the only company with advanced enough technology to deliver these throughputs -- so the implication must be (A). But then that raises the question, how could they have a cost advantage over competitors?

(4) It also raises a question of whether they'd be capable of a technological innovation that produces that cost advantage, or whether the cost advantage is supposed to be produced by other factors such as supply chain advantages or more efficiently vertically integrated business divisions.

(5) Since you said you know the CEO from past associations, do you think that he is just lying, or would he not be saying that they're developing a new product line which solves a market problem (cost-effective 1 Gbps throughput for 5G applications) unless it was true?

(6) If they're lying, then why would they invest in expanded manufacturing capability and consolidate their offices into a new, larger HQ -- just as part of a smoke and mirrors act to sucker investors by keeping the growth narrative charade going?

(7) If (6) is true then why have there been some insider purchases this year (albeit not large ones) and no insider sales since 2018? Is it because you think that management are just using the company to milk an overpaid salary and insider sales would threaten to kill the goose by undermining the growth narrative charade?

(8) Why did Intracoastal Capital and Sabby make large 13G investments when the price was much higher as far as I can tell? Do these investments give some credibility to AMPG's claims about innovating into larger market categories, or are there alternative explanations that are more likely?

Unfortunately I have a large bag at a cost average of 4.70, but the whole small cap market has been getting murdered lately. I guess I've either been suckered badly or AMPG is in fact at a turning point with the new chip design facility and supposedly pending designs that are supposedly patentable and supposedly solve the under-1gbps throughput limitation suffered by other chips.

Exited today and recovered my losses by scalping BENE. I've come to believe that qnta is a scam. The main reason is that the CEO did essentially the same thing but in the veterinary niche some years ago with a company called "Petlife" - after that company was dead and shareholders decimated, it seems that he had the idea to repeat the same model but with human medicine, simply changing "Petlife" to "Medolife." It's a matter of record that Mikaelian was CEO of Petlife at one point.

The other thing that made me lose confidence was the press releases about their "study" results always say something like "conducted at one of the leading cancer research facilities in the US" etc. but without actually naming the institution. No good reason for that. Also, none of the studies are peer reviewed so there's no way to know if their results are faked.

Finally, the particular species of scorpion whose venom is used by Medolife doesn't have any peer reviewed evidence of efficacy. The various studies about effective venom that I could find were done with a different species that doesn't live in the Dominican Republic. It's not safe to assume that the blue scorpion of Medolife has effective or useful venom just because some species do. And if their venom was not that useful or peer reviewed it would explain why they've never generated sales revenues from selling the venom itself despite the venom supposedly being so valuable. It wouldn't be valuable if from a different species than the ones proven to have useful venom.

Even if it's a scam, doesn’t mean it can't run. RDGL was a scam imo and had crazy runs. But I wasn't comfortable holding anymore after reflecting on the above, especially the history with Petlife (PTLF).

GLTA

If the polarization technology works as claimed and the patent is defensible and unique, what is the bear case? The main reason why this wouldn't be bought out for a billion dollars imo is if the company is incapable of executing on anything that will actually generate revenue. For example, why does the Aelia store website have a space between Tony Hawk and "apostrophe s" so that the apostrophe is facing the wrong direction in the font being used, in the big ad blurb saying it's his favorite product? This is just ridiculously stupid that they have a billion dollar IP and can't type properly. Who the hell manages the marketing? Someone else with the CEO's last name, probably his son, as it seems on the management team page of the IR website. Not a good look.

So either we have to conclude that the consumer retail side is managed incompetently or is there to strengthen the narrative as a sucker stock which exists to pay salaries for the family.

That leaves the most realistic pathway to shareholders profiting being a buyout or licensing deal, or other b2b type windfall such as government contracts for Escozine as a Covid treatment. If the polarization technology is real and truly proprietary / protected then it should be worth billions of dollars but maybe they can't even accomplish anything with it before the patent expires. Maybe the fact that patents expire is why patent plays aren't safe bets when the management is incompetent on execution.

It honestly scares me how there is absolutely no hype around this no matter what PRs get released. It means nobody cares, either because no one believes them or because truthfulness wouldn't mitigate the above bearish cases enough to gamble on the company.

Any thoughts about this analysis? Agree or disagree?

In since .051, been agonizing to hold this for months through all these PRs that can't help the price or volume.

What QNTA is proving clearly is that in OTC land, PRs don't mean anything in themselves because everything is assumed to be a scam until proven otherwise by filings. So aside from bullish filings, the only possible reason that an OTC stock can get volume and price increases is simply because people are chasing or buying into a narrative based on chasing, because the price is already moving up on hype or speculation (likely concomitant with pump and dump coordinated by insiders, Twitter followers, or maybe a market wide pump of penny stocks like happened last December, etc.).

Another factor that I think is hurting pennies badly now compared with before: I think all of the casino-like high risk market participation has diverted into crypto shitcoins, away from penny stocks. Does anyone think that until or unless crypto shitcoins are more heavily regulated (may not happen for years), penny stocks runs are going to be increasingly rare / a thing of the past?

What other explanation could there be for how QNTA has failed to run at all and just bleeds endlessly without dilution occurring?

I got out at a huge loss today because of this Washington Post article:

https://www.washingtonpost.com/national/health-science/clinic-pitches-unproven-treatments-to-desperate-patients-with-tips-on-raising-the-cash/2019/12/01/fe94cfcc-d3c6-11e8-8c22-fa2ef74bd6d6_story.html

Also this article:

https://ipscell.com/2021/03/fact-check-lung-health-institute-cell-therapies-for-lung-disease/

These are in the top several Google results for "Lung Health Institute." It seems very possible that Wagner being in the stock will make it pump more in the future but I don't want to hold it since I think the company is a scam. GLTA

To clarify, Wagner is the majority controlling owner (60%) through
FWHC BRIDGE, LLC which he is the sole manager of. So I think as long as he holds $8m in this and retains majority ownership, maybe he is not going to let the shareholders get too badly screwed over the medium to long term.

Also, I will add that Wagner doesn't seem to invest that often, these are the only filings for him that I see:

https://www.sec.gov/edgar/browse/?CIK=0001066152

The others were in 1998 and 2006.

I found the filing detailing Todd Wagner's investment: https://docoh.com/filing/1591165/0001066152-21-000003/4

It looks like he owns over $8m as a 10% owner and hasn't sold any since acquiring the shares in Q3 2020:

https://docoh.com/company/1591165/HCYT/insider-ownership-history


Based on this maybe an FDA application is going to be an upcoming catalyst. At least eventually.

The market cap is only 10 million right now. So it doesn't need to be a cure to have further upside IMO. As for the benefits or lack thereof from the treatment, I don't know how to ferret that out from the study they did. It's not great that it lacked a control group, but on the other hand, it was stated that COPD would normally be progressively degenerative and improvement was observed instead of degeneration, so that may mean that simply a lack of the pulmonary function worsening is already a substantive benefit. I'm not a medical expert so I don't know, just saying what seems plausible from my uneducated vantage point.

With ending up 150%, do you believe that this is likely to bounce or have continuation, or do you think it's more likely to go dead for months until another PR may happen months away?

This ran to .99 on 510,000 volume in February. It seems impossible that on over 18 million volume the top was 0.30 and it won't bounce at all.

Maybe I'm a fool but I doubled down around .07 so I have a cost average of .114 now.

Also as far as I can tell, it didn't even have PR for the February run.

If this is the first in a sequence of PRs then the run should keep going. I readily admit this is an ugly upthrust on the daily chart though.

It doesn't make any sense to me that this was just crushed like this on such high volume. But the upthrust in February is even worse, it pumped to .99 and closed at .14 on February 11th.

On January 21st was the last communication to shareholders before today's PR, and they claimed they are pursuing FDA application and other catalysts for which they received investment from the billionaire Todd Wagner:

https://ir.hcyte.com/news-events/press-releases/detail/242/h-cyte-issues-letter-to-shareholders

Maybe I'm a sucker but I don't understand how the run is already dead. If this was a scam company how could they have gotten Todd Wagner to invest in it? Are they just making that up?

Where can you see / how can you tell that the company is dumping shares?

Hi, can you elaborate? By 8 notes do you mean warrants or debt that they owe?

Longs who still have faith in Mexus, please articulate why:

What are the odds at this point that Mexus isn't a scam?

I got in at 0.0347 on the PRs about gold production at the Santa Elena site being imminent.

Since then, I've witnessed a March 15th PR announcing that blasting would occur "next week" and now an April 5th PR re-announcing blasting the following week again (April 12th). It seems like we are being breadcrumbed BS to keep us hanging onto the shares while they bleed out from toxic debt conversions. In the meantime we keep getting announcements and nothing actually gets accomplished. Given the broken promises of "next week" "soon" etc. for significant gold production, is it even possible at this point that the CEO isn't a crook?

As a thought experiment, is there a plausible explanation for how he isn't a crook and the company is legitimate? I mean in light of the fact that the PRs keep pushing dates back and breaking timeline estimates. I would like to hear the best counter-argument for why I should keep holding in light of this. As is, I feel like I was scammed because they keep announcing and re-announcing things while nothing gets done and the price keeps dumping in the meantime.

Thanks, that is a really helpful, informative reply. I'm a noob and am hoping you wouldn't mind educating me: what is the play here then? I mean what scenario makes buying shares of a shell worth the risk? I guess it's a lotto ticket type of bet that eventually a real company will acquire the shell and the existing shareholders of the shell now suddenly have equity in the real company. But how unlikely is that to happen vs. a delisting?

Is this just an empty shell?
The 4/22/2020 1Q Holders: "The list represents up to 50 of the largest holders in the company."

Shares Held:
BC Financial Services PLLC 1 1 0.001 12/31

And on ThinkorSwim, showing Market Cap 0 and Shares 3,498. That can't be right. What's the story with this ticker?

lol! You're hilarious. Fortunatly Glefdar is just an alias which I chose becuase I thought it's funny. As for the warrants, I'm still interested in a clear answer about whether the vested warrants with a .03 exercise price should be expected to create .03 stock price resistance. It would appear to be the case now.

Yes, I generally would agree with you that hiring or composing a company of a bunch of geezers on their way out is a recipe for a "show up to cash the check" mentality, not a real growth mentality.

Am interested in your thoughts about the warrants issue as well, per my post a few minutes ago

I just posted a new msg about this - was there no buying above 0.03 because of vested warrants exercisable at 0.03?

3m vested warrants creating strong price resistance at .03?

Want to make sure I understand this from the last 10-q:

"On April 25, 2019, Wayne Homschek joined the Board of Directors as an independent Director who will aid in corporate strategy, financing and investor relations. He will be paid $5,000 per month for one year and receive a warrant, exercisable into 3,000,000 shares of common stock at an exercise price of $0.03 per share. As per the agreement, 1,500,000 warrants vest in six months and the remaining balance of 1,500,000 shall vest one year later."

That means the first half of the warrants vested October 2019, and the second half of the warrants vested in April 2020.

I guess we can't determine how many of the warrants have already been exercised but shouldn't we expect a lot of price resistance above .03 due to this? Or am I missing something. I'm a noob so maybe someone can explain the right way to interpret the situation.

New board created for UNIF - under the radar, recently uplisted from Pink Sheets, low float, AR expected soon off four quarters of net income increases compared to previous year:
https://investorshub.advfn.com/U&I-Financial-Corp-(UniBank)-UNIF-36779/

New board created for UNIF - under the radar, recently uplisted from Pink Sheets, low float, AR expected soon off four quarters of net income increases compared to previous year:
https://investorshub.advfn.com/U&I-Financial-Corp-(UniBank)-UNIF-36779/

Net income in 2018 increased 42% vs previous year for Q2, 88% for Q3, and reached record high of $4.5m for Q4. Uplisted from Pink Sheets to OTCQX at around New Year's and despite these events, prices has not moved much but volume has increased very significantly in the last 6 weeks or so. (PRs referencing these numbers are all linked here under "News": https://www.tradingview.com/symbols/OTC-UNIF)

01.29.2019 - U & I Earnings Release 4Q 2018
https://www.unibankusa.com/Portals/UniBank/Documents/U%20I%20Financial%20Corp.%20Earnings%20Release%204Q%202018.pdf

This is just the PR but the annual report itself for 2018 isn't posted on the investor relations page of the website yet. I called the investor relations contact and she said it's usually posted by end of March, and it will be posted like the others.

12.26.2018 - U & I Upgraded to OTCQX Best Market
https://www.unibankusa.com/Portals/UniBank/Documents/12_26_2018_OTCQX_upgrade_pressrelease.pdf

Investor Relations page with annual reports here: https://www.unibankusa.com/en-us/About-Us/Investor-Relations

The pump and dump (ending price lower than before it started) on Monday and now the 15% drop today have been worse than anyone could have imagined IMO. I've personally never bought a stock that held less than 0% of its gains after a huge pump and then dumped relentlessly in the following days. I thought all the catalysts would mean gains but I think that the truth of what happened is their cash burn to revenue ratio is too bad. It's obscene for them to burn $4.4m in one quarter to only make $1.4m in revenue. I feel like an idiot.

How is this supposed to go up when the market response to the ER was negative and people are shorting the shit out of it nonstop?

I feel like I made an enormous mistake.

I'm hoping that the clinical research results, when they release within the next month, will cause another spike up that is strong enough to eat the 8.8m $1.50 warrants. If the price can stabilize around $1.10-1.20 leading up to then, that would be good. What I don't like is that the ask is really stacked heavy in AH, which looks like a poor market response to the ER.

Thanks for sharing. Interesting point about the warrants. Maybe the warrants can mean less probability of high short term reward (because a moonshot requires eating the warrants) but also less risk, i.e. maybe it's why even with all the shorting AYTU isn't going below $1. That's as long as they don't do another offering or R/S. But that seems like a reasonable bet to me since they just did the October offering. Also even though the Form 4s were not actual insider buys (just vested shares as stock rewards I guess - point is that the insiders did not pay money for the shares), it still shows that they have skin in the game. Whether or not they paid out of pocket for those shares, they wouldn't want their value to crash. The shares are vested until 2028 and I presume that they'd want to see steady growth in the value over that time. In that case hopefully we're at the turning point of the company. If it will ever turn around towards sustainability without further dilution then based on what I've seen, I think this would have to be the turning point (Q4 '18 or Q1 '19).

Lol. I'm not a pumper or a griefer which means that I'm trying to engage in honest discussion. I know it's an unheard of concept on these boards.

I'm long 7,600 shares at $1.10 entry because I figure that all the upcoming catalysts including the potential of drastically improved EPS should make this a safe bet into the end of Q4/Q1. But the $1.50 warrants are clearly the thing holding it back and I don't know if or when they can be eaten - can it happen today if the ER is good enough (and how good would that have to be), or will it take months? I have no idea.

If you check my profile it should show that I've only started trading less than two months ago, so I'm still learning. It would be nice to get actual honest input here, not just pumpers calling moon and dumpers calling dumpster fire with twisted facts and lies. Maybe I'm on the wrong website. But I have seen people on ihub occasionally who are willing to share honest and informed analysis. Do you have an opinion about the warrants?

That was a pump on this PR (https://www.benzinga.com/content/12629473/aytu-bioscience-enters-3-billion-cough-and-cold-market-and-expands-primary-care-por) but it became a dump presumably because of people shorting the $1.50 resistance where the warrants would be exercised. On the upside if the ER is really good and if a short squeeze happens which makes this eat the outstanding warrants then AYTU could skyrocket. I'm not sure what magnitude of ER strength would be required and how likely/unlikely it is for the warrants to be eaten. There are also other catalysts coming up.

List of AYTU catalysts / reasons for positive outlook:
1) Conference call today with ER (https://www.accesswire.com/viewarticle.aspx?id=526679)
2) Clinical research primary readout coming soon (https://investorshub.advfn.com/uimage/uploads/2018/9/26/aroqdaytu4.png) since Dec. 1st is primary completion date of study( https://clinicaltrials.gov/ct2/show/NCT03203681?term=ranjith+ramasamy&rank=1)
3) There were five Form 4s, with a total of over 1.5m shares of insider acquisiton recently (https://ih.advfn.com/stock-market/NASDAQ/aytu-bioscience-inc-AYTU/news). These are vested shares which can be exercised in 10 years (not insider buying) but people seem to be confused that it's insider buying so it could be having an effect.
4) PR about Form 13G a few weeks ago, with institutional investment of 9.9% (https://www.benzinga.com/news/18/10/12498748/aytu-bioscience-13g-from-cvi-investments-shows-9-9-stake)
5) Completed an offering earlier in October so risk of another offering / dilution before another pump on these catalysts is low IMO (I'm reading the last offering they completed recently is enough funding for them for the next 1-2 years)
6) Next ER should also reflect that they received more sales from their entry into market 3-5 months ago selling drug Zolpimist ($1.8b market)
7) Hard to tell what the current mcap and float is after last offering but should be around $10m mcap and 30m float I think.
8). Again, 8.8m convertible notes at $1.50 which means $1.50 resistance will be very hard to overcome, but huge short % of float would mean that if there's a short squeeze, can run very hard.
9) $10 price target by analyst was released in PR 2-3 weeks ago. So that could help with the pump by setting a high PT in people's minds
10) The Monday PR about the new drug license at least got the stock on lots of people's radar (tons more watchers now), but not sure if it will also increase shorting and make the resistance stronger if/when it pumps again because of that Monday pump dumping so hard.

It all boils down to eating the 8.8m of $1.50 convertible warrants, right?

Is it possible for the ER to be good enough to actually make this stock eat all of the convertible warrants that are priced at $1.50 per share? If the warrants can't be eaten then this can never hold above $1.50 resistance.

FYI I'm holding 7,500 shares with a cost average of $1.10. I didn't sell at 1.65 because I thought continuation would happen but with how badly the pump dumped yesterday, I'm skeptical that all those warrants can be eaten. Even with that enormous volume yesterday, we didn't even come close to holding above $1.50 during normal market hours.

What would have to happen with these upcoming catalysts (including ER) for a short squeeze above $1.50 to happen and how likely are those things really?

Acerus is licensing Natesto for different regions than the US, just like AYTU is licensing Natesto for the US. So how does it help us whatever Acerus is doing? Natesto patent isn't owned by AYTU, it's just licensed. If I'm wrong or missing something please explain

That is Acerus - what does that have to do with Aytu?

Conference call Nov. 7th: https://www.accesswire.com/viewarticle.aspx?id=526679

"Wednesday, October 31, 2018 8:05 AM
Live Conference Call and Webcast Scheduled for November 7, 2018, at 4:30 p.m. ET

ENGLEWOOD, CO / ACCESSWIRE / October 31, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the fiscal first quarter 2019 on November 7, 2018, at 4:30 p.m. ET. The company will review recent accomplishments and provide an overview of its business and growth strategy.

Conference Call Information:

Interested participants and investors may access the conference call by dialing either:

1-877-407-9124 (toll-free)

1-201-689-8584 (international)

The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days.

A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 1-919-882-2331 (international) and using the replay access code 40285."